Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 1/20 | 0.59 |
| ▸ | CSF1R | P07333 | 3/20 | 0.50 |
| ▸ | KDR | P35968 | 6/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
| ▸ | RAF1 | P04049 | 4/20 | 0.45 |
| ▸ | BRAF | P15056 | 4/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15574613 | 0.89 | DDR2 (0.60) | DDR2CSF1RKDRMAPK14RAF1 | |
| SCHEMBL15574266 | 0.87 | DDR2 (0.56) | DDR2CSF1RKDRMAPK14RAF1 | |
| SCHEMBL2025625 | 0.84 | DDR2 (0.52) | DDR2CSF1RKDRMAPK14RAF1 | |
| SCHEMBL13603766 | 0.84 | KDR (0.62) | DDR2CSF1RKDRMAPK14RAF1 | |
| SCHEMBL13603772 | 0.82 | KDR (0.54) | CSF1RKDRMAPK14RAF1BRAF | |
| SCHEMBL4373389 | 0.81 | KDR (0.52) | DDR2CSF1RKDRMAPK14RAF1 | |
| SCHEMBL30678636 | 0.81 | DDR2 (0.52) | DDR2CSF1RKDRMAPK14RAF1 | |
| SCHEMBL15574523 | 0.80 | KDR (0.58) | DDR2CSF1RKDRMAPK14RAF1 | |
| SCHEMBL27989476 | 0.79 | KDR (0.54) | DDR2CSF1RKDRMAPK14RAF1 | |
| SCHEMBL15574246 | 0.79 | DDR2 (0.50) | DDR2CSF1RKDRRAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
| EP-2890380-A2 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | Merck Patent GmbH (DE) | 2015-07-08 | — | — | EP | disclosed |
| CN-104602690-A | DDR2 inhibitors for the treatment of osteoarthritis | MERCK PATENT GMBH | 2015-05-06 | — | — | CN | disclosed |
| WO-2014032755-A2 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2014-03-06 | — | — | WO | disclosed |
| WO-2014032755-A2 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2014-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | DDR2, DDR1, DDRGK1 | DDR2 1/4885CSF1R 885/4885KDR 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.